Medical Oncology Department, Hospital Universitario de Guadalajara, Guadalajara, Spain.
Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain.
Clin Transl Oncol. 2018 Jan;20(1):57-68. doi: 10.1007/s12094-017-1783-2. Epub 2017 Nov 13.
Androgen deprivation treatment was the only treatment available for metastatic prostate cancer until recently, with docetaxel as the only treatment with a proven survival benefit in castration-resistant prostate cancer (CRPC). Several drugs have been approved in the castration-resistant disease (sipuleucel-T, cabazitaxel, abiraterone, enzalutamide, radium-223). More recently, docetaxel and abiraterone have been moved to the hormone-sensitive disease setting, achieving better patient survival. The purpose of this article is to define the state of the art in the treatment of prostate carcinoma.
雄激素剥夺治疗是转移性前列腺癌的唯一治疗方法，直到最近，多西他赛是唯一一种在去势抵抗性前列腺癌（CRPC）中具有生存获益的治疗方法。在去势抵抗性疾病中，已经批准了几种药物（sipuleucel-T、卡巴他赛、阿比特龙、恩扎鲁胺、镭-223）。最近，多西他赛和阿比特龙已被用于激素敏感性疾病的治疗，从而提高了患者的生存率。本文的目的是定义前列腺癌治疗的最新进展。
